Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab or sintilimab for refractory aggressive recurrent respiratory papillomatosis
ChiCTR2200059627Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of bevacizumab and sintilimab in Laryngeal papilloma (RRP) (4 arms), sponsored by Shandong Cancer Hospital. Primary endpoints: Frequency of debulking surgery during the 12 months before and 12 months after treatment in Group A and Objective response in Groups B, C, and D. Planned start May 2022; status: not yet recruiting.
02
Drugs
bevacizumabsintilimab
03
Conditions
Laryngeal papilloma (RRP)
Beyond the preview
Go deeper on ChiCTR2200059627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059627.